Sign in

Trial result ·

Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This study tested rilzabrutinib, a drug taken by mouth, in adults with ITP. Their ITP was persistent or chronic and had been treated before. First, people were put by chance on the drug or a dummy pill. Then 180 people moved into a 28-week open phase. In this phase, everyone took rilzabrutinib 400 mg by mouth. The trial ran at 103 centres in 24 countries.

What they found

Of 198 people who took the drug, 46 had stable platelet responses. Of 65 people first given the dummy pill, 14 had a lasting response. A full response was seen in 42 of 180 people. Side effects tied to the drug showed up in 46 of 180 people. The most common were low-grade diarrhoea and nausea. Some people had serious side effects, such as a lung disease and infections. No one died during the open phase. Scores for tiredness and bleeding stayed the same or got better.

What it means for patients

The authors say platelet responses kept going and sometimes got better. This held even for people who did not respond at first. They say the drug also helped with tiredness and bleeding. They judged the drug's safety to be good.

Why it is not certain yet

In the open phase, everyone knew they were taking the drug. That phase had no dummy pill group to compare with. The middle follow-up time was 196 days. So the long-term effects are not yet known. A longer extension phase will look at this further. Another trial, LUNA4, will test the drug earlier in treatment.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial.

PubMed · PMID 42753771

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Immune thrombocytopenia (ITP) publications